Join
Live feed
·
PRReleasevia Quantisnow
Zymeworks Inc. logo

Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress

ByQuantisnow·Wall Street's wire, on your screen.
ZYME· Zymeworks Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZYME (Zymeworks Inc.) and more on Quantisnow.